MicroRNA Expression Levels and Histopathological Features of Colorectal Cancer.
Antigens, CD34
/ metabolism
Biomarkers, Tumor
/ genetics
Cell Proliferation
/ genetics
Colorectal Neoplasms
/ genetics
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Ki-67 Antigen
/ metabolism
Male
MicroRNAs
/ genetics
Middle Aged
Neoplasm Staging
Neovascularization, Pathologic
/ genetics
CD34
Colorectal cancer
Ki-67
MicroRNA
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
pubmed:
7
2
2018
medline:
30
8
2019
entrez:
7
2
2018
Statut:
ppublish
Résumé
Non-coding RNAs have opened a new window in cancer biology. MicroRNAs (miRNAs), as a family of non-coding RNAs, play an important role in the gene regulation. The aberrant expression of these small molecules has been documented to involve in colorectal cancer (CRC) pathogenesis. This study aimed to examine the expression of miRNAs in CRC and to correlate their expression levels with histological markers (Ki-67 and CD34). Tumor tissues and matched normal adjacent tissues were collected from 36 patients with newly diagnosed CRC. Immunohistochemical (IHC) staining of tumor tissues was performed for Ki-67 (proliferation) and CD34 (angiogenesis) markers, and the immunoexpression staining scores were obtained. A polyadenylation SYBER Green quantitative real-time PCR technique was used to quantify the expression of a panel of five CRC-related miRNAs (hsa-miR-21, 31, 20a, 133b, and 145). Histopathological (H) scores and miRNA expression levels were correlated with clinicopathological features including the degree of differentiation, staging, and lymphovascular invasion. Our results showed the significant difference between the two groups for the expression level of hsa-miR-21, hsa-miR-31, hsa-miR-145, and miR-20a (P < 0.001), but not for hsa-miR-133b (P = 0.57). Further analysis revealed an inverse significant correlation between hsa-miR-145 and Ki-67 (r = - 0.942, P < 0.001). While a positive correlation was observed between hsa-miR-21 and Ki-67 (r = 0.920, P < 0.001), and hsa-miR-21 and CD34 (r = 0.981, P < 0.001). Also, a positive correlation between hsa-miR-31 and Ki-67 (r = 0.913, P < 0.001), hsa-miR-31 and CD34 (r = 0.798, P < 0.05), hsa-miR-20a and Ki-67 (r = 0.871, P < 0.001), and hsa-miR-20a and CD34 (r = 0.890, P < 0.001) was found. Dysregulation of miRNAs and correlation with molecular histopathology indicate a biological role for miRNAs in various cellular processes including cell proliferation and angiogenesis in CRC development. On the other hand, the pattern of miRNA expression and its correlation with histological markers are potentially valuable to apply as diagnostic biomarkers for CRC.
Identifiants
pubmed: 29404790
doi: 10.1007/s12029-018-0055-x
pii: 10.1007/s12029-018-0055-x
doi:
Substances chimiques
Antigens, CD34
0
Biomarkers, Tumor
0
Ki-67 Antigen
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
276-284Références
J Biol Chem. 2000 Apr 14;275(15):10802-11
pubmed: 10753873
Mod Pathol. 2003 Apr;16(4):376-88
pubmed: 12692203
Nature. 1992 Oct 29;359(6398):845-8
pubmed: 1279432
Mol Cancer Res. 2003 Oct;1(12):882-91
pubmed: 14573789
Tumour Biol. 2003 Aug-Sep;24(4):209-18
pubmed: 14654716
Mod Pathol. 2005 Jan;18(1):143-52
pubmed: 15297858
Development. 1992 Feb;114(2):521-32
pubmed: 1592003
Cancer Res. 2005 Aug 15;65(16):7065-70
pubmed: 16103053
Carcinogenesis. 2007 Jan;28(1):28-37
pubmed: 16774940
J Cell Physiol. 2006 Oct;209(1):56-66
pubmed: 16775835
Nat Genet. 2006 Sep;38(9):1060-5
pubmed: 16878133
Free Radic Biol Med. 2006 Nov 15;41(10):1521-33
pubmed: 17045920
Yale J Biol Med. 2006 Dec;79(3-4):131-40
pubmed: 17940623
Oncogene. 2008 Apr 3;27(15):2128-36
pubmed: 17968323
Oncology. 2007;72(5-6):397-402
pubmed: 18196926
Cell Res. 2008 Mar;18(3):350-9
pubmed: 18270520
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14082-7
pubmed: 18779589
Circ Res. 2009 Feb 27;104(4):476-87
pubmed: 19150885
Oncology. 2009;77(1):12-21
pubmed: 19439999
Curr Opin Genet Dev. 2009 Jun;19(3):205-11
pubmed: 19446450
BMC Cancer. 2009 May 28;9:163
pubmed: 19473551
Int J Biochem Cell Biol. 2010 Aug;42(8):1273-81
pubmed: 20026422
Blood. 2010 Jun 10;115(23):4631-3
pubmed: 20538815
J Cardiovasc Transl Res. 2010 Jun;3(3):251-5
pubmed: 20560046
Lab Invest. 2011 Jan;91(1):157-65
pubmed: 20661226
PLoS One. 2011 Apr 22;6(4):e19139
pubmed: 21544242
Chin J Cancer. 2011 Jun;30(6):371-80
pubmed: 21627859
Nucleic Acids Res. 2012 Jan;40(2):761-74
pubmed: 21917858
Nat Rev Mol Cell Biol. 2012 Apr 04;13(5):283-96
pubmed: 22473468
Cold Spring Harb Perspect Med. 2013 Feb 01;3(2):a006643
pubmed: 23169571
Cancer Biol Med. 2013 Mar;10(1):22-7
pubmed: 23691441
Nat Rev Clin Oncol. 2013 Jul;10(7):377-89
pubmed: 23712187
PLoS One. 2013 Aug 08;8(8):e71472
pubmed: 23951172
Theranostics. 2013 Nov 30;3(12):943-52
pubmed: 24396505
Virchows Arch. 2014 Mar;464(3):379-91
pubmed: 24487787
Mol Med Rep. 2014 Jul;10(1):283-91
pubmed: 24737193
Daru. 2014 Jun 05;22:47
pubmed: 24902843
World J Clin Oncol. 2014 Aug 10;5(3):382-92
pubmed: 25114853
Biol Trace Elem Res. 2015 Jun;165(2):131-4
pubmed: 25663478
Mol Ther. 2015 Jul;23(7):1234-1247
pubmed: 25903473
Cancer Cell Int. 2015 Apr 02;15:38
pubmed: 25960691
Iran J Basic Med Sci. 2015 Sep;18(9):856-61
pubmed: 26523217
Mol Med Rep. 2016 Jan;13(1):909-14
pubmed: 26647993
Oncotarget. 2016 Jul 19;7(29):45199-45213
pubmed: 27286257
Acta Med Iran. 2016 Jun;54(6):352-8
pubmed: 27306340
Acta Med Iran. 2016 May;54(5):302-7
pubmed: 27309477
Iran J Basic Med Sci. 2016 Jun;19(6):601-7
pubmed: 27482340
Jundishapur J Microbiol. 2016 Mar 05;9(5):e27297
pubmed: 27540448
Cancer Biomark. 2016 Sep 26;17(3):301-311
pubmed: 27802206
Asian Pac J Cancer Prev. ;(18):2101-2108
pubmed: 28843229
Cancer Invest. 2017 Nov 26;35(10):625-632
pubmed: 29243990
Curr Med Mycol. 2017 Mar;3(1):25-29
pubmed: 29302627
Mol Cell Biol. 1996 Sep;16(9):4604-13
pubmed: 8756616